EGFR and lung adenocarcinoma: Genomic profiling of ctDNA samples can identify therapeutic targets by locating driver and resistance mutations Analysis of the ctDNA of 8388 advanced lung adenocarcinoma and NSCLC patients by 70 gene NGS panel (Guardant360 assay) identified oncogene driver mutations in 48.8% of the samples, the most frequent mutations being EGFR followed by KRAS.